Abstract
Orbital fibrosis is a hallmark of tissue remodeling in thyroid-associated ophthalmopathy (TAO). Previous studies have shown that interleukin (IL)-11 plays a pivotal profibrotic role in various inflammatory and autoimmune diseases. However, the expression pattern of IL-11 in patients with TAO and whether IL-11 is mechanistically linked with pathological fibrosis remains unknown. In this study, we investigated IL-11 levels in the serum and orbital connective tissue of patients with TAO, and evaluated the correlation of these levels with the patient’s clinical activity score. We also evaluated the expression pattern of IL-11Rα in orbital connective tissue. Furthermore, we elucidated the regulatory factors, profibrotic function, and downstream signaling pathways for IL-11 in TAO using in vitro studies. IL-11 levels in serum and orbital connective tissues were increased in patients with TAO, as compared with healthy controls. In addition, both levels were positively correlated with disease activity. Single-cell RNA sequencing of orbital connective tissue indicated that IL-11Rα was dominantly expressed in orbital fibroblasts (OFs). RNA sequencing of paired unstimulated and transforming growth factor (TGF)-β1-stimulated samples demonstrated that upregulation of IL-11 expression defined the dominant transcriptional response. IL-11 signaling was also confirmed to be downstream of TGF-β1 and IL-1β. Therefore, we deduced that IL-11 protein is secreted in an autocrine loop in TAO. We also indicated that IL-11 mediated the profibrotic phenotype switch by inducing the expression of myofibroblast differentiation markers, including α-smooth muscle actin and collagen type I α1, which could be abrogated by an anti-IL-11 neutralizing antibody. Furthermore, we revealed that extracellular regulated protein kinase may be a crucial factor in the pro-fibrotic, translationally specific signaling activity of IL-11. These data demonstrate that IL-11 plays a crucial role in orbital fibroblast phenotype switching and may be a potential therapeutic target candidate for the treatment of TAO.
Highlights
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune ocular disease related to dysregulated thyroid gland activity, Graves’ hyperthyroidism, and is called Graves’ orbitopathy
We found that serum IL-11 concentrations in patients with TAO were significantly elevated compared to those in healthy controls (Figure 1A, mean TAO: 66.6 ± 25.42 pg/mL; mean controls: 38.14 ± 10.49 pg/mL; P < 0.0001)
Single-cell RNA sequencing of orbital connective tissue indicated that IL-11Ra was predominantly expressed in Orbital fibroblasts (OFs)
Summary
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune ocular disease related to dysregulated thyroid gland activity, Graves’ hyperthyroidism, and is called Graves’ orbitopathy. The main pathological process involves inflammatory infiltration of orbital tissue, extracellular matrix (ECM) production, orbital tissue remodeling, and orbital volume expansion, which provide a mechanical foundation for illustrating the clinical features of periorbital edema, conjunctival hyperemia, eyelid retraction, diplopia, protrusion, exposure keratitis, and compressive optic neuropathy [1, 3–5]. This appearance-destroying and vision-threatening ocular disease seriously affects the quality of patients’ lives. The pathological hallmarks of orbital fibrosis in TAO are centered on myofibroblasts [10], which display two typical features: secretion of ECM and contractility, with the expression of a-smooth muscle actin (a-SMA), resulting in excess accumulation of ECM proteins and increased tissue stiffness [11, 12]. The initial triggers that activate the fibroblast-tomyofibroblast transition in TAO remain unclear
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
